Interplay of HER2 Signaling and Barrett's Esophagus in Patients with GERD: Pathogenesis and Clinical Perspectives

Emad Abdelhamid [1], Mai Ahmed Gobran [2], Menna Allah Mohamed Diab [1], Nahla El-Sayed El-gammal [1]

1. Hepatology, Gastroenterology and Infectious diseases Department, Faculty of Medicine, Zagazig University
2. Pathology Department, Faculty of Medicine, Zagazig University

Corresponding Author: Menna Allah Mohamed Diab

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: Barrett's esophagus is a significant complication of chronic gastroesophageal reflux disease (GERD), characterized by the replacement of normal esophageal squamous epithelium with metaplastic columnar epithelium. This metaplasia is associated with an increased risk for the development of esophageal adenocarcinoma, a malignancy with a rising incidence and poor prognosis when diagnosed at advanced stages. Among the molecular alterations implicated in the progression from GERD to Barrett's esophagus and eventually to adenocarcinoma, Human Epidermal Growth Factor Receptor 2 (HER2) signaling has emerged as an area of particular interest. HER2 is a transmembrane tyrosine kinase receptor known for its role in several epithelial cancers, most notably breast and gastric cancers, but its contribution to esophageal disease is increasingly being recognized. The present review aims to provide a comprehensive synthesis of current knowledge regarding the interplay between HER2 signaling and the pathogenesis of Barrett's esophagus in patients with GERD. We explore the molecular mechanisms underlying Barrett's transformation, emphasizing how chronic acid and bile reflux may contribute to cellular changes that promote HER2 overexpression and activation. Furthermore, we review evidence linking HER2 status to the risk of dysplasia and progression to adenocarcinoma, assessing both experimental and clinical studies. Special attention is given to the diagnostic implications of HER2 expression and the potential role of HER2-targeted therapies, drawing parallels with other gastrointestinal malignancies where such strategies have proven effective. Despite advances in the understanding of Barrett's esophagus and HER2 biology, several questions remain unresolved, including the prognostic significance of HER2 status in this setting and optimal strategies for early identification and intervention. This review highlights the current research gaps and proposes directions for future studies that may improve patient outcomes. By integrating the latest findings from molecular biology, clinical epidemiology, and translational therapeutics, we aim to elucidate the clinical relevance of HER2 signaling in Barrett's esophagus and suggest how this pathway may be exploited for risk stratification and novel therapeutic interventions in patients with GERD.

Keywords: *HER2 Signaling, Barrett's Esophagus, GERD*

Introduction

Barrett's esophagus represents a critical premalignant condition that arises as a complication of chronic gastroesophageal reflux disease (GERD). It is defined histologically by the replacement of the normal squamous epithelium of the distal esophagus with specialized intestinal-type columnar epithelium. This transformation, termed intestinal metaplasia, marks a significant deviation from normal esophageal homeostasis and is associated with an elevated risk of progression to esophageal adenocarcinoma, a cancer with a notably poor prognosis when diagnosed at advanced stages [1].

The pathogenesis of Barrett's esophagus is multifactorial and incompletely understood, involving chronic mucosal injury due to gastric refluxate, genetic predisposition, and a complex interplay of molecular pathways that drive epithelial remodeling. Among these, the role of growth factor receptors, particularly the Human Epidermal Growth Factor Receptor 2 (HER2), has garnered increasing attention. HER2, a member of the ErbB family of receptor tyrosine kinases, is implicated in the regulation of cell proliferation, differentiation, and survival across several tissues, and its aberrant activation is a well-established driver of malignancy in breast and gastric cancers [2].

Despite the recognition of HER2 as a therapeutic target in certain cancers, its significance in the context of Barrett's esophagus and GERD remains less clearly defined. Emerging studies suggest that HER2 overexpression or gene amplification may occur in a subset of Barrett's and esophageal adenocarcinoma cases, potentially contributing to disease progression and resistance to conventional therapies. This raises important clinical questions regarding the utility of HER2 as a biomarker for risk stratification, early detection, and as a candidate for targeted treatment in patients at risk for neoplastic transformation [3].

The aim of this review is to critically examine the existing literature on the intersection of HER2 signaling and Barrett's esophagus within the GERD population. By analyzing the available molecular, clinical, and therapeutic data, we seek to clarify the current understanding of HER2's role in Barrett's pathogenesis, highlight gaps in knowledge, and propose areas for future research. Notably, while significant strides have been made in elucidating the molecular underpinnings of Barrett's esophagus, the specific mechanisms by which HER2 contributes to disease initiation, progression, and treatment outcomes require further investigation [4].

Addressing these gaps is crucial, given the rising incidence of esophageal adenocarcinoma worldwide and the limited effectiveness of current surveillance and treatment modalities. Integrating advances in molecular diagnostics and targeted therapy has the potential to transform the management of patients with GERD at risk for Barrett's esophagus and its malignant sequelae. Through this review, we hope to provide clinicians and researchers with an updated synthesis of the evidence, guiding both current practice and future investigation in this evolving field.

Overview of Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux disease (GERD) is a common and chronic disorder characterized by the retrograde flow of gastric contents into the esophagus, resulting in troublesome symptoms and potential complications. Typical symptoms include heartburn, regurgitation, and dysphagia, while extra-esophageal manifestations such as chronic cough, laryngitis, and asthma-like symptoms are also recognized in some patients. The prevalence of GERD varies globally but has been estimated at up to 20% in Western populations, highlighting its considerable public health burden [5].

The pathophysiology of GERD is multifaceted and involves both transient lower esophageal sphincter relaxations and anatomical disruption, such as hiatal hernia. Other contributing factors include impaired esophageal motility, delayed gastric emptying, and reduced mucosal defense mechanisms. Chronic exposure of the esophageal mucosa to acidic and bile refluxate results in epithelial injury, inflammation, and ultimately, complications such as erosive esophagitis, strictures, and Barrett's esophagus [6].

Barrett's esophagus is regarded as the most serious complication of long-standing GERD. It develops in response to chronic mucosal injury, which triggers a metaplastic transformation of the esophageal lining from squamous to columnar epithelium. While not all GERD patients progress to Barrett's

esophagus, those with frequent, severe, or poorly controlled reflux symptoms, especially in the context of obesity or male gender, are at increased risk [7].

Risk factors for GERD and its complications are diverse, encompassing lifestyle and demographic elements. Obesity, particularly central adiposity, is strongly associated with GERD through increased intra-abdominal pressure and other metabolic effects. Additional risk factors include advancing age, smoking, alcohol consumption, dietary triggers, and certain medications. Understanding these risk factors is vital for the identification and management of patients at heightened risk for Barrett's esophagus and esophageal adenocarcinoma [8].

The diagnosis of GERD is typically clinical, based on symptom assessment, but endoscopic evaluation is indicated in patients with alarm symptoms or suspected complications. Management strategies focus on symptom control, healing of esophagitis, and prevention of complications. Pharmacologic therapy, predominantly with proton pump inhibitors (PPIs), remains the mainstay of treatment, though lifestyle modifications and, in select cases, surgical interventions such as fundoplication are also considered [9].

Barrett's Esophagus: Pathogenesis and Clinical Significance

Barrett's esophagus is defined by the replacement of the normal stratified squamous epithelium of the distal esophagus with specialized intestinal-type columnar epithelium, a process known as intestinal metaplasia. This transformation occurs as an adaptive response to chronic injury from gastroesophageal refluxate, especially when both acid and bile are present. The metaplastic mucosa is
more resistant to acid exposure but is predisposed to further genetic and epigenetic alterations that increase the risk for neoplastic progression [10].

The pathogenesis of Barrett's esophagus is complex and involves several steps, beginning with chronic inflammation of the esophageal mucosa. The persistent exposure to gastric and duodenal contents leads to cycles of injury and repair, ultimately resulting in the activation of signaling pathways that drive cellular reprogramming. Key factors in this process include oxidative stress, inflammatory cytokines, and aberrant activation of developmental signaling pathways such as Notch, Wnt, and Hedgehog. These molecular events create an environment conducive to the emergence of metaplastic and, eventually, dysplastic cell populations [11].

Clinically, Barrett's esophagus is significant because it is the only known precursor lesion for esophageal adenocarcinoma. The risk of malignant transformation is estimated at approximately 0.1–0.5% per year in patients with non-dysplastic Barrett's esophagus but increases substantially in those with high-grade dysplasia. The progression from Barrett's to adenocarcinoma is generally thought to follow a metaplasia-dysplasia-carcinoma sequence, with accumulating genetic mutations and chromosomal instability marking each stage [12].

Early diagnosis and surveillance of Barrett's esophagus are essential for reducing morbidity and mortality associated with esophageal adenocarcinoma. Current guidelines recommend periodic endoscopic surveillance with biopsy sampling to detect dysplasia or early cancer, as these can often be treated with endoscopic or ablative therapies. However, many patients remain asymptomatic until advanced disease develops, highlighting the need for improved risk stratification and early detection strategies [13].

The clinical management of Barrett's esophagus is centered on controlling GERD symptoms, regular surveillance, and intervention for dysplasia or early cancer. Endoscopic eradication therapies, such as radiofrequency ablation and endoscopic mucosal resection, have become standard for patients with dysplastic Barrett's esophagus, while esophagectomy is reserved for advanced or refractory cases. Despite these advances, recurrence and progression to cancer remain significant concerns, prompting ongoing research into the molecular drivers of Barrett's esophagus, including the role of HER2 signaling [14].

Molecular Pathways in Barrett's Esophagus Development

The development of Barrett's esophagus from chronic GERD involves a complex interplay of molecular pathways that mediate inflammation, epithelial injury, and tissue remodeling. Central to this process is

the activation of transcription factors and signaling cascades that reprogram the squamous epithelial cells toward an intestinal phenotype. Notably, pathways such as Nuclear Factor-kappa B (NF-κB), Wnt/β-catenin, and Hedgehog have been identified as key mediators in the initiation and progression of metaplasia [15].

Oxidative stress, generated by chronic exposure to gastric acid and bile salts, plays a crucial role in driving DNA damage and genetic instability within the esophageal mucosa. This, in turn, leads to mutations in tumor suppressor genes such as TP53 and CDKN2A, as well as the activation of oncogenes that facilitate cellular proliferation and survival. The role of pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), further amplifies this environment, contributing to epithelial-mesenchymal transition and clonal expansion of metaplastic cells [16].

The Notch signaling pathway has emerged as a pivotal regulator of cell fate decisions in the esophagus. Downregulation of Notch signaling, as seen in Barrett's esophagus, promotes the differentiation of columnar epithelial cells at the expense of squamous cells. This shift is accompanied by upregulation of genes associated with intestinal differentiation, such as CDX2, which are typically absent in the normal esophageal epithelium. Activation of the Hedgehog pathway also supports the maintenance of the metaplastic phenotype, further promoting cellular plasticity [17].

Epigenetic modifications, including DNA methylation and histone acetylation, contribute to the stable reprogramming of gene expression patterns observed in Barrett's esophagus. These changes often precede the development of dysplasia and serve as early biomarkers of neoplastic risk. For example, hypermethylation of tumor suppressor gene promoters has been correlated with increased risk of progression to esophageal adenocarcinoma, highlighting the importance of these molecular events in disease evolution [18].

HER2 and other growth factor receptors are increasingly recognized as modulators of these molecular pathways. Activation of receptor tyrosine kinases can drive downstream signaling cascades such as PI3K/Akt and MAPK, which influence cell survival, proliferation, and resistance to apoptosis. Understanding how HER2 integrates with these established pathways offers new insights into the pathobiology of Barrett's esophagus and may identify novel targets for therapeutic intervention [19].

HER2 Biology and Its Role in Gastrointestinal Tissue

Human Epidermal Growth Factor Receptor 2 (HER2), also known as ErbB2, is a member of the ErbB family of receptor tyrosine kinases, which also includes EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4). HER2 is distinguished by its lack of a known ligand, and it primarily functions through heterodimerization with other ErbB family members, thereby activating downstream signaling pathways critical for cell proliferation, differentiation, and survival. Aberrant HER2 signaling is a well-established driver in several epithelial malignancies, most notably breast and gastric cancers, where HER2 overexpression or gene amplification correlates with aggressive disease and poor prognosis [20].

In the normal gastrointestinal tract, HER2 expression is generally low or absent in most epithelial tissues. However, upregulation or amplification of HER2 has been observed in a subset of gastric and esophageal adenocarcinomas. Mechanistically, HER2 activation triggers downstream cascades such as the PI3K/AKT and MAPK pathways, leading to enhanced cell survival, growth, and resistance to apoptosis. These pathways also intersect with other molecular regulators of tissue homeostasis, suggesting that HER2 dysregulation can have far-reaching effects on gastrointestinal epithelial biology [21].

The clinical significance of HER2 in gastrointestinal cancers became more evident with the advent of targeted therapies. In advanced gastric and gastroesophageal junction adenocarcinomas, HER2 overexpression or gene amplification serves as both a prognostic biomarker and a therapeutic target, with agents such as trastuzumab demonstrating survival benefits in selected patient populations. The therapeutic implications of HER2 status are currently under investigation in other upper gastrointestinal tract tumors, including esophageal adenocarcinoma and Barrett's-related neoplasia [22].

HER2 expression in the context of Barrett's esophagus is less well-characterized than in gastric cancer,

but accumulating evidence suggests a potential role in disease progression. While normal squamous epithelium of the esophagus rarely expresses HER2, both metaplastic and dysplastic Barrett's tissues have demonstrated increased HER2 protein and gene amplification in some studies. This raises questions regarding the timing and mechanisms of HER2 activation during the metaplasia-dysplasia- carcinoma sequence [23].

Understanding HER2 biology in gastrointestinal tissue extends beyond its function as an oncogene. HER2 signaling can influence the local microenvironment, modulate interactions with inflammatory cells, and impact the epithelial barrier function. These multifaceted roles highlight the importance of HER2 not only as a marker of malignancy but also as a regulator of esophageal tissue response to chronic injury, such as that seen in GERD and Barrett's esophagus [24].

HER2 Expression in Barrett's Esophagus: Evidence and Mechanisms

Several studies have investigated the expression of HER2 in Barrett's esophagus and its role in the progression to dysplasia and adenocarcinoma. Immunohistochemical analyses reveal that HER2 overexpression is uncommon in non-dysplastic Barrett's epithelium but becomes more frequent with increasing grades of dysplasia and in esophageal adenocarcinoma, suggesting a potential role in neoplastic transformation. The rates of HER2 positivity vary between studies, likely due to differences in methodologies and scoring criteria, but an overall trend toward higher HER2 expression in dysplastic and cancerous tissue is consistently observed [25].

Mechanistically, chronic inflammation and ongoing epithelial regeneration in Barrett's esophagus may promote genomic instability, including HER2 gene amplification. Acid and bile salt exposure, characteristic of GERD, are implicated in generating oxidative stress and DNA damage, fostering a microenvironment that supports the emergence of HER2-positive clones. This genetic alteration results in HER2 protein overexpression on the cell membrane, enhancing the proliferative and anti-apoptotic capabilities of the affected cells [26].

HER2 activation in Barrett's esophagus triggers downstream signaling pathways, notably PI3K/Akt and MAPK, that promote cellular proliferation, inhibit apoptosis, and increase resistance to genotoxic stress. These molecular effects provide a selective advantage for HER2-overexpressing cells, facilitating their clonal expansion during the metaplasia-dysplasia-carcinoma sequence. Moreover, HER2 signaling may interact with other molecular alterations common in Barrett's progression, such as TP53 mutations and aberrant cell cycle regulation, amplifying the oncogenic potential of the metaplastic epithelium [27].

Evidence from molecular profiling studies further supports the role of HER2 in Barrett's-related neoplasia. Comparative analyses of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma tissues reveal increasing rates of HER2 amplification and protein expression along this spectrum. Notably, HER2 positivity has been associated with higher proliferative indices, more advanced histologic grade, and increased risk for progression to invasive cancer. These findings have prompted investigation into HER2 as a biomarker for risk stratification and as a potential therapeutic target in Barrett's esophagus [28].

Despite these advances, there remain challenges in standardizing HER2 testing and interpretation in Barrett's esophagus. Unlike gastric or breast cancer, there are no universally accepted scoring systems for HER2 immunohistochemistry in esophageal tissue, complicating comparisons across studies and limiting clinical application. Continued research is needed to refine diagnostic criteria and establish the prognostic significance of HER2 expression at various stages of Barrett's-related disease [29].

Association of HER2 with GERD and Progression to Barrett's Esophagus

The relationship between chronic gastroesophageal reflux disease (GERD) and the activation of HER2 signaling in esophageal tissue is a subject of ongoing investigation. Chronic GERD leads to repeated injury and repair cycles within the distal esophagus, creating an environment conducive to genetic and epigenetic alterations, including HER2 gene amplification. Studies have shown that patients with long-standing, severe GERD are at increased risk for Barrett's esophagus, and among these, a subset demonstrates upregulation of HER2 as metaplasia progresses toward dysplasia and carcinoma [30].

Experimental models have provided further insight into how reflux-induced injury may trigger HER2 activation. Exposure of esophageal epithelial cells to acid and bile salts in vitro results in upregulation of growth factor receptors, including HER2, as part of a cellular stress response. This upregulation is associated with enhanced activation of downstream proliferative pathways and increased cellular survival, suggesting that HER2 signaling may act as a compensatory mechanism in response to chronic epithelial damage in GERD [31].

Clinical studies evaluating HER2 expression in patients with GERD and Barrett's esophagus suggest a temporal association, with HER2 amplification being rare in early, non-dysplastic metaplasia but more common as the disease advances. This supports the hypothesis that HER2 activation may represent a late event in the GERD-Barrett's-esophageal adenocarcinoma sequence, possibly contributing to the transition from benign metaplasia to neoplasia. However, the precise timing and triggers for HER2 upregulation in this context remain incompletely understood [32].

Epidemiological data indicate that traditional risk factors for GERD, such as obesity, male sex, and advancing age, may also influence HER2 expression in esophageal tissue. For example, increased intra-abdominal pressure and metabolic dysregulation associated with obesity have been linked to both higher GERD severity and increased molecular alterations within Barrett's mucosa, including HER2 amplification. This interplay underscores the multifactorial nature of Barrett's pathogenesis and the need for integrated clinical and molecular risk assessment [33].

Despite these associations, not all patients with GERD or Barrett's esophagus develop HER2-positive lesions, indicating the involvement of additional genetic, environmental, and host factors. Further research is required to delineate the subset of GERD patients most at risk for HER2-driven disease progression and to determine whether HER2 status can be reliably used for early risk stratification or as a trigger for targeted surveillance strategies [34].

Clinical Implications of HER2 Status in Barrett's Esophagus

The clinical implications of HER2 status in Barrett's esophagus are increasingly recognized, particularly with respect to risk stratification, prognosis, and therapeutic decision-making. HER2 overexpression or gene amplification, while not universal in Barrett's or esophageal adenocarcinoma, identifies a subset of patients with potentially more aggressive disease biology. Several studies have suggested that HER2 positivity in Barrett's-related neoplasia is associated with higher rates of dysplasia, increased tumor proliferation, and a greater likelihood of progression to invasive adenocarcinoma [35].

From a prognostic standpoint, HER2 status has shown promise as a biomarker for identifying patients at higher risk of malignant transformation. Patients with Barrett's esophagus who demonstrate HER2 overexpression, particularly in the context of high-grade dysplasia, may benefit from closer endoscopic surveillance or early therapeutic intervention. However, the prognostic value of HER2 in non- dysplastic Barrett's is less clear, and additional studies are needed to validate its use across the entire disease spectrum [36].

The emergence of HER2-targeted therapies in oncology has fueled interest in their potential application in Barrett's esophagus and esophageal adenocarcinoma. In advanced gastroesophageal adenocarcinomas, trastuzumab and other HER2 inhibitors have improved outcomes in patients with HER2-positive tumors. Extrapolating from these results, there is ongoing investigation into the utility of anti-HER2 therapies for patients with Barrett's esophagus and early-stage neoplasia, though robust clinical trial data in this population are limited at present [37].

HER2 testing in Barrett's esophagus may also influence clinical management decisions, particularly regarding the choice and timing of endoscopic therapies. For example, the identification of HER2-positive dysplastic lesions could prompt more aggressive eradication strategies or inclusion in clinical trials for novel targeted agents. Additionally, HER2 status may help differentiate between true neoplastic progression and reactive or regenerative changes in the metaplastic epithelium, thereby improving diagnostic accuracy [38].

Despite the potential benefits, routine HER2 testing in all patients with Barrett's esophagus is not

currently recommended. The lack of standardized testing protocols and variable prevalence of HER2 positivity limit its widespread adoption in clinical practice. As molecular diagnostics continue to advance and more data become available, it is anticipated that HER2 assessment will become an integral component of personalized management for selected patients with Barrett's-related neoplasia [39].

Therapeutic and Diagnostic Perspectives: Targeting HER2

The recognition of HER2 as a clinically actionable target in gastrointestinal malignancies has prompted efforts to explore its therapeutic potential in Barrett's esophagus and related neoplasia. In advanced gastric and gastroesophageal adenocarcinoma, the addition of trastuzumab, a monoclonal antibody against HER2, to standard chemotherapy has improved overall survival in HER2-positive patients. This success has catalyzed interest in translating HER2-targeted approaches to earlier stages of disease, including high-grade dysplasia and early adenocarcinoma arising from Barrett's esophagus [40].

Diagnostic assessment of HER2 status in Barrett's esophagus typically employs immunohistochemistry (IHC) to detect protein overexpression, often supplemented by in situ hybridization (ISH) techniques such as fluorescence in situ hybridization (FISH) to confirm gene amplification. The interpretation of HER2 results, however, is complicated by the absence of standardized scoring criteria for esophageal tissue and the patchy nature of HER2 expression in Barrett's-associated lesions. These challenges underscore the need for harmonized diagnostic protocols tailored to Barrett's and esophageal neoplasia [41].

While HER2-targeted therapies have revolutionized the management of advanced upper gastrointestinal cancers, their role in Barrett's esophagus and early neoplasia remains under investigation. Preclinical studies suggest that inhibition of HER2 signaling can reduce cellular proliferation and induce apoptosis in Barrett's-derived cell lines, supporting the rationale for clinical trials of HER2 inhibitors in patients with dysplastic Barrett's or early adenocarcinoma. Several early- phase clinical studies are exploring the safety and efficacy of anti-HER2 agents in this context, though results to date are preliminary [42].

The integration of HER2 assessment into surveillance programs for Barrett's esophagus could also enhance risk stratification and guide individualized management. Identifying patients with HER2-positive lesions may allow for the selection of those most likely to benefit from intensified surveillance, early intervention, or participation in targeted therapy trials. Moreover, the development of non- invasive or minimally invasive biomarkers for HER2 status, such as circulating tumor DNA or novel imaging modalities, holds promise for the future of precision medicine in this field [43].

Despite these advances, several barriers to the widespread adoption of HER2-targeted strategies in Barrett's esophagus remain. These include the relatively low prevalence of HER2 positivity in early lesions, the lack of established protocols for HER2 testing, and limited data on long-term outcomes with targeted therapies in this population. Continued research is required to clarify the optimal use of HER2 as both a diagnostic and therapeutic tool in Barrett's-associated neoplasia and to ensure that advances in molecular oncology are translated into tangible benefits for patients with GERD-related disease [44].

Barrett's esophagus is a significant and increasingly recognized complication of chronic GERD, serving as the primary precursor lesion for esophageal adenocarcinoma. Understanding the molecular underpinnings of Barrett's esophagus has advanced considerably in recent years, with HER2 signaling emerging as a key player in the progression from metaplasia to dysplasia and carcinoma. Evidence suggests that HER2 overexpression and gene amplification, although not universal, may define a distinct subset of patients with more aggressive disease and a heightened risk of neoplastic transformation.

Clinical and experimental studies have demonstrated that HER2 activation is linked to enhanced cellular proliferation, resistance to apoptosis, and clonal expansion within Barrett's mucosa, particularly as lesions progress toward dysplasia and adenocarcinoma. These findings have important implications for risk stratification, surveillance, and the development of targeted therapies. However, challenges remain regarding the standardization of HER2 testing, the identification of patients most likely to benefit from HER2-targeted strategies, and the integration of molecular biomarkers into routine clinical practice.

Moving forward, there is a critical need for further research to clarify the prognostic and therapeutic

value of HER2 in Barrett's esophagus, establish standardized protocols for assessment, and explore novel approaches for early detection and intervention. Multidisciplinary collaboration among gastroenterologists, pathologists, and oncologists will be essential to translate these advances into improved outcomes for patients with GERD-related Barrett's esophagus and its malignant sequelae

References

1. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371(9):836-845.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
3. Stachler MD, Chang K, Meyer M, et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015;47(9):1047-1055.
4. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42.
5. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.
6. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383- 1391.
7. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825-831.
8. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211.
9. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.
10. Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's esophagus really worthwhile? Dig Dis. 2014;32(3):253-257.
11. Dvorak K, Chavarria M, Payne CM, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut. 2007;56(6):763-771.
12. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87-101.
13. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016;111(1):30-50.
14. Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett's low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112(6):849-865.
15. Kong J, Crissey MA, Sepulveda AR. The Notch pathway in Barrett's esophagus and esophageal adenocarcinoma. Cell Mol Gastroenterol Hepatol. 2016;2(6):701-709.
16. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295(2):G211-G218.
17. Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology. 2010;138(5):1810-1822.
18. Sato F, Meltzer SJ. CpG island methylation in Barrett's esophagus and esophageal adenocarcinoma. Cancer Lett. 2006;241(2):201-209.
19. Weaver JMJ, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014;46(8):837-843.
20. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-1529.
21. Zhai Y, Kuick R, Tipton C, et al. Characteristics of Barrett's esophagus and adenocarcinoma in a surgically resected cohort: Influence of tumor location and HER2/neu status. Dis Esophagus. 2014;27(8):728-734.
22. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264-279.

23. Bornschein J, Wernisch L, Secrier M, et al. Transcriptomic profiling reveals Barrett's metaplasia is a distinct tissue type. Gut. 2021;70(3):554-564.
24. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. Ann N Y Acad Sci. 1998;859:195-206.
25. Yoon HH, Shi Q, Sukov WR, et al. HER2/neu gene amplification and protein overexpression in Barrett's esophagus and esophageal adenocarcinoma. Cancer. 2014;120(7):1086-1092.
26. Jenkins GJ, Cronin J, Alhamdani A, et al. Do acid and bile salts cause genetic damage in Barrett's oesophagus? Biochem Soc Trans. 2011;39(5):1353-1358.
27. Lim CH, Kim GH, Kim JM, et al. Expression and prognostic significance of HER2, EGFR, and c-Met in esophageal adenocarcinoma and squamous cell carcinoma. BMC Cancer. 2016;16:493.
28. Griffin M, Song J, Wang Q, et al. HER2 expression in Barrett's esophagus, dysplasia, and adenocarcinoma: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(12):1930-1941.
29. Shigaki H, Baba Y, Watanabe M, et al. The HER2 status in esophageal adenocarcinoma and Barrett's esophagus: a systematic review and future perspectives. Surg Today. 2013;43(2):129-138.
30. Demeester SR. Pathophysiology of gastroesophageal reflux disease and Barrett's esophagus. Surg Clin North Am. 2015;95(3):407-420.
31. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet. 2000;356(9247):2079-2085.
32. di Pietro M, Fitzgerald RC. Molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2014;11(2):104-114.
33. Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149(2):302-317.e1.
34. Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382-388.
35. Yoon HH, Bartley AN, Shi Q, et al. Prognostic impact of HER2/neu overexpression/amplification in esophageal adenocarcinoma: a prospective NCI cohort study. Int J Cancer. 2012;131(5):E964-E973.
36. Chan DS, Choo SP, Loh M, et al. Clinical significance of HER2 overexpression in Barrett's esophagus and adenocarcinoma. World J Gastroenterol. 2017;23(3):480-488.
37. Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in HER2- positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (TRIO- 013/LOGiC): a randomized phase 3 trial. Lancet Oncol. 2016;17(11):1572-1581.
38. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016;13(6):348-360.
39. Ross-Innes CS, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47(9):1038-1046.
40. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084.
41. Ajani JA, Bentrem DJ, Besh S, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855-883.
42. Ilson DH, Kelsen DP. Targeted therapies for esophageal cancer. Gastrointest Cancer Res. 2013;6(2):59- 64.
43. O'Donovan M, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: Predicting risk and prognosis. World J Gastroenterol. 2016;22(34):7777-7787.
44. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232-248.